Research Applications for Striatech Products

Vascular and Metabolic Disease: Visual Endpoints in Diabetic Retinopathy, Stroke, and Ischaemic CNS Injury Research

Disruption of blood flow and glucose homeostasis driving retinal and CNS visual pathway injury. Diabetic retinopathy and ischemic stroke share neurovascular mechanisms and converge on quantitative visual endpoints.
Research Chapter Vascular and Metabolic Disease: Diabetic Retinopathy and Stroke

Disruption of blood flow and glucose homeostasis driving retinal and CNS visual pathway injury. Diabetic retinopathy and ischemic stroke share neurovascular mechanisms and converge on quantitative visual endpoints.

7
Application Areas
5
FAQs answered
Part of CNS & Neurodegeneration
Main Application Areas
Diabetic Retinopathy
Neurovascular Injury
Retinal Ischemia-Reperfusion Injury
Stroke
Additional Topics
Blindness
Neuroinflammation
Retinal Degeneration
Introduction

What Is the Vascular and Metabolic Disease Application Area?

Vascular and metabolic disease in a preclinical context encompasses the full range of pathological states in which systemic or local disruption of blood flow, glucose homeostasis, or metabolic regulation produces injury to the retina, optic nerve, or CNS visual pathway.

Two major paradigms define the application area. The first is diabetic retinopathy (DR), in which chronic hyperglycaemia drives a cascade of neurovascular injury – pericyte loss, endothelial dysfunction, blood-retinal barrier (BRB) breakdown, microglial activation, and progressive retinal neurodegeneration – that ultimately produces visual impairment. The second is ischaemic CNS injury, encompassing stroke and retinal ischaemia-reperfusion (I/R) injury, in which acute interruption of blood supply causes rapid neuronal death, white matter demyelination, and secondary retinal degeneration through shared neurovascular mechanisms.

Although DR and stroke are distinct disease entities, their underlying biology converges on a common set of molecular and cellular processes: neuroinflammatory activation driven by innate immune mediators such as the STING/cGAMP pathway (Ge et al, 2025, J Neuroinflammation), neurovascular unit dysfunction, complement and TNF-alpha-mediated secondary neuronal injury, and loss of retinal ganglion cell (RGC) pathway integrity. This biological convergence is the defining feature of the vascular-and-metabolic application area: whether the trigger is sustained hyperglycaemia or an acute ischaemic event, the retina and optic nerve respond with a predictable and quantifiable functional deficit that is measurable non-invasively using the optomotor reflex paradigm.

Preclinical research in this area addresses two complementary objectives. The first is mechanistic: understanding how vascular and metabolic insults translate to retinal neurodegeneration, identifying the molecular mediators of this process, and defining the therapeutic windows within which intervention can preserve function. The second is translational: developing functional endpoints that bridge preclinical rodent models to clinically relevant disease measures, validating neuroprotective and anti-inflammatory treatment strategies, and establishing the retina as a non-invasive biomarker window for systemic CNS vascular disease. Striatech instruments serve both objectives.

Vision: A Window into the brain 

Why Does Vascular and Metabolic Disease Affect Vision – and Why Does That Matter for Non-Vision Researchers?

If your primary research focus is diabetes, stroke, cerebrovascular disease, or metabolic syndrome rather than the eye, the following points explain why visual function readouts are directly relevant to your work and how they can strengthen your experimental design.

The retina is the only CNS tissue that is directly and non-invasively observable in the living animal, and the retinal vasculature is an anatomical and functional extension of the cerebral vasculature. The same microvascular pathology that drives diabetic nephropathy and diabetic neuropathy also drives diabetic retinopathy, and the retinal microvasculature is now well established as a surrogate biomarker for cerebrovascular health in human clinical research. In rodent models, chronic hyperglycaemia produces retinal neuroinflammation, pericyte loss, and BRB breakdown on a time course that parallels brain microvascular injury (Holden et al, 2024, J Neurochem). Measuring visual acuity with the OptoDrum provides a quantitative, non-invasive, in vivo readout of this neurovascular degeneration process in the same animals in which you are also characterising systemic metabolic parameters – without additional animal use, anaesthesia, or ophthalmological specialist involvement.

For stroke researchers, the argument is equally direct. The posterior visual cortex is among the most frequently affected brain regions in human posterior circulation stroke, and cortical visual field deficits are among the most common and disabling sequelae of cerebrovascular events. In experimental stroke models, ischaemic injury to the visual pathway produces measurable visual acuity deficits detectable by OptoDrum and, when cortical visual processing is the specific subject of study, by AcuiSee (Colon Ortiz et al, 2022, Cell Death Dis). The retinal vasculature is directly supplied by branches of the same carotid and ophthalmic arterial territory implicated in anterior circulation stroke, meaning that the retina captures the neurovascular injury that is also occurring in the brain. Visual function measurement thus provides stroke researchers with a non-invasive functional biomarker of neurovascular injury severity and treatment response that no other accessible CNS region can provide.

A further advantage is the compatibility of visual function measurement with existing behavioural batteries. The OptoDrum measurement does not require motor function or active exploration, making it applicable in metabolic disease models where body weight, adiposity, and reduced locomotor activity confound motor performance tests such as the rotarod or Morris water maze. In diabetic rodent models with peripheral neuropathy, grip strength deficits, or post-stroke motor impairment, the OMR provides an independent functional axis that is orthogonal to the confounds affecting standard motor and cognitive assessments.

Animal Models

Common Animal Models for Vascular and Metabolic Disease Research

  • Streptozotocin (STZ) model – type 1 diabetes: Systemic STZ injection ablates pancreatic beta cells, inducing severe hyperglycaemia within 48–72 hours. Diabetic retinopathy features – pericyte loss, microaneurysms, BRB breakdown, microglial activation, and RGC dysfunction – develop over weeks to months. Visual function loss is progressive and detectable by OptoDrum from approximately 8–12 weeks post-induction (Holden et al, 2024). The STZ model is the most widely used rodent DR paradigm and the primary reference model for this pillar.
  • db/db mouse and Zucker diabetic fatty (ZDF) rat – type 2 diabetes: Genetic models of insulin resistance and type 2 diabetes that develop obesity, hyperglycaemia, and dyslipidaemia on a metabolic syndrome background. Retinal microvascular and neurodegenerative changes develop more slowly than in the STZ model but more closely replicate the human type 2 DR time course. Visual function decline is trackable by OptoDrum over the natural disease progression.
  • High-fat diet (HFD) model: Diet-induced obesity and insulin resistance that replicates the metabolic syndrome context of human type 2 DR. Retinal neuroinflammation and subtle visual function changes are detectable at earlier stages than overt microvascular pathology, making the OMR a sensitive screen for early neuroinflammatory retinopathy in the metabolic disease context.
  • Middle cerebral artery occlusion (MCAo) – stroke: Transient or permanent focal cerebral ischaemia that models ischaemic stroke. MCAo produces secondary retinal and visual pathway injury through neurovascular disruption, with measurable visual function deficits detectable by OptoDrum (Colon Ortiz et al, 2022, Cell Death Dis.). When posterior cortical regions are involved, AcuiSee can additionally assess cortical visual processing deficits that the subcortical OMR does not capture.
  • Retinal ischaemia-reperfusion (I/R) injury model: Acute elevation of intraocular pressure (IOP) to supra-systolic levels (90–100 mmHg) for 45–120 minutes, followed by reperfusion, replicates the pathophysiology of retinal artery occlusion and ischaemic optic neuropathy. Complement activation, RIPK1-driven necroptosis, and TNF-alpha signalling are activated within hours; RGC loss and visual acuity deficits are measurable by OptoDrum within 7–14 days (Yu et al, 2022, Biomaterials).
  • Ischaemic white matter demyelination model: Focal ischaemia of white matter tracts, including the optic nerve, induced by vascular occlusion or chemical demyelination, produces early myelin loss and secondary axon damage. OptoDrum documents the visual functional consequence of optic nerve ischaemic demyelination and any treatment-induced recovery (Xue et al, 2023, Brain Pathol.).
  • Oxygen-induced retinopathy (OIR) model: Neonatal hyperoxia followed by room-air return induces retinal neovascularisation and vascular pathology relevant to proliferative diabetic retinopathy and retinopathy of prematurity. Visual function measured by OptoDrum captures the functional consequence of aberrant vascular development on the photoreceptor and RGC layers.
Research Questions

How Can Striatech Tools support Your Study?

Select a question that matches your research objective to see which instruments are relevant, what challenge they address, and what the published evidence shows.
01
How Can I Measure Visual Dysfunction Longitudinally in Diabetic Retinopathy Models?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

The OptoDrum provides a fully automated, non-invasive measurement of spatial visual acuity (cycles per degree) and contrast sensitivity via the optomotor reflex in awake, freely moving rodents, enabling longitudinal tracking of visual function decline in STZ, db/db, and HFD diabetic models without anaesthesia, animal training, or ophthalmological specialist equipment. Holden et al (2024) demonstrated that chronic hyperglycaemia produces a progressive, quantifiable optomotor acuity deficit that parallels retinal neuroinflammatory and neurovascular changes, establishing OptoDrum as the reference functional readout for the longitudinal characterisation of DR in rodents.

The challenge

Diabetic retinopathy in rodents develops slowly, with functional deficits typically emerging weeks to months after the metabolic insult. This slow progression is clinically faithful but experimentally challenging: it demands frequent, reproducible measurements in the same animals across an extended time course, and it places a premium on endpoints that are sensitive enough to detect the subtle early-stage functional changes that precede overt vascular pathology. Classical DR endpoints – fluorescein angiography for vascular leakage, electroretinography for photoreceptor and inner retinal function, and retinal flat-mount analysis for pericyte loss and acellular capillary counts – provide high-resolution mechanistic information but require anaesthesia, specialised equipment, or terminal tissue collection, making them impractical for the high-frequency longitudinal monitoring that DR time-course studies require.

The optomotor reflex resolves these constraints. Because the OMR is mediated subcortically by the accessory optic system and nucleus of the optic tract, it does not require cortical integrity, anaesthesia, or any form of animal conditioning. A measurement takes approximately four minutes per animal, and the same animal can be retested daily without habituation or cumulative procedural burden. Holden et al. (2024, J Neurochem) demonstrated that this approach successfully captures the progressive visual acuity and contrast sensitivity decline in a chronic hyperglycaemia DR model, with deficits emerging at time points consistent with retinal neuroinflammatory onset and preceding the development of overt vascular lesions.

For researchers interested in rod-mediated (scotopic) visual function – which may be affected at earlier stages of DR due to rod photoreceptor metabolic vulnerability to hyperglycaemia – the ScotopicKit extension enables testing under near-dark conditions in the same instrument. When scotopic and photopic visual acuity are both tracked longitudinally, the comparison provides a more complete functional profile of disease progression and can discriminate between inner retinal (RGC/OMR pathway) and outer retinal (photoreceptor) degeneration.

Also see: Diabetic Retinopathy and Neurovascular Injury

How Striatech products help

OptoDrum
Automated, non-invasive measurement of photopic visual acuity (cycles per degree) and contrast sensitivity via the optomotor reflex. Tracks progressive visual function decline in STZ, db/db, and HFD diabetic models longitudinally in the same animals, without anaesthesia or training. Approximately 4 minutes per animal; daily testing is feasible.
ScotopicKit
Extends OptoDrum testing to scotopic (rod-mediated) conditions at step-wise luminance reductions of 1 log unit. Enables detection of rod photoreceptor functional deficits in early DR, when outer retinal metabolic vulnerability may produce scotopic deficits before photopic acuity declines. Requires dark-adaptation protocol.
DarkAdapt
Light-tight, ventilated housing box ensuring complete and reproducible dark-adaptation prior to scotopic OMR testing. Essential for consistent ScotopicKit measurements across all longitudinal time points in a DR study.
AcuiSee
Measures visual acuity and contrast sensitivity via an operant conditioning paradigm that requires cortical visual processing. In DR models where the research question specifically concerns whether retinal dysfunction has propagated to impair cortical visual representation (for example, in late-stage DR with extensive inner retinal loss or in studies of diabetes-related cortical neurodegeneration) AcuiSee provides the cortically- mediated complement to the subcortical OptoDrum readout. The two instruments together allow investigators to distinguish between a purely retinal/subcortical deficit and one that extends to cortical visual processing.
Non-aversive Animal Platform
Minimises handling stress during testing. Particularly relevant in diabetic rodent models where animals may be debilitated by neuropathy, reduced locomotor activity, or altered pain sensitivity, and where conventional restraint risks confounding the optomotor response with stress-related suppression.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Holden et al (2024) J Neurochem.
    Systematic longitudinal characterisation of visual function decline in a chronic hyperglycaemia model using OptoDrum, demonstrating that progressive loss of optomotor acuity and contrast sensitivity correlates with retinal neuroinflammatory and neurovascular changes over the disease time course. The study established that OptoDrum-based visual acuity is a sensitive, early-window functional readout of DR progression in rodents.
  • Ge et al (2025) J Neuroinflammation.
    cGAMP-driven innate immune activation produces iBRB disruption and a measurable visual acuity deficit in a DR model, providing complementary evidence that the OMR is sensitive to the functional consequences of early neurovascular barrier failure in diabetic retinal disease.
02
How Does Neuroinflammation and Blood-Retinal Barrier Breakdown Drive Visual Loss in Diabetic Retinopathy?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

In diabetic retinopathy, innate immune activation (including STING pathway signalling via cGAMP, microglial priming, and TNF-alpha-driven endothelial dysfunction) drives breakdown of the inner blood-retinal barrier (iBRB), leading to retinal neurodegeneration and measurable visual acuity loss detectable by OptoDrum. Ge et al (2025) demonstrated this connection directly, showing that pharmacological manipulation of the cGAMP/STING pathway alters iBRB integrity and optomotor-measured visual function, establishing a causal molecular link between retinal innate immunity and DR-associated visual dysfunction.

The challenge

Neuroinflammation is now recognised as a central and early pathogenic mechanism in diabetic retinopathy, rather than a downstream consequence of late vascular damage. Within weeks of hyperglycaemia onset, microglial cells in the inner retina adopt a proinflammatory phenotype, NLRP3 inflammasome activation elevates retinal IL-1beta, and the innate immune sensor STING is activated by mitochondrial DNA damage products including cGAMP. Each of these processes contributes to the breakdown of tight junction proteins in retinal endothelial cells and pericytes, disrupting the iBRB and allowing plasma proteins, inflammatory cells, and neurotoxic mediators to enter the retinal parenchyma. The resulting neuroinflammatory microenvironment drives RGC dysfunction, inner nuclear layer atrophy, and ultimately the photoreceptor degeneration that produces irreversible visual loss.

Mechanistic research on DR neuroinflammation has historically relied on end-point histological and biochemical assays – GFAP immunostaining for Muller cell activation, IBA-1 quantification of microglial density, tight junction protein Western blotting, FITC-dextran permeability assays – that are terminal and provide no information about the functional visual consequence of the molecular pathology being studied. The OptoDrum fills this gap by providing a behavioural functional correlate that links the observed molecular events to a real-world visual outcome: researchers can confirm not only that cGAMP disrupts the iBRB biochemically, but that this disruption produces a quantifiably worse optomotor acuity in the same animals (Ge et al, 2025, J Neuroinflammation). This functional grounding strengthens the translational significance of any mechanistic finding and provides the evidence base for claiming that the pathway under study is genuinely disease-relevant rather than merely statistically associated with a histological endpoint.

Also see: Neuroinflammation and Autoimmune CNS Disease, Neuroinflammation and Diabetic Retinopathy.

How Striatech products help

OptoDrum
Provides the functional correlate linking BRB disruption and retinal neuroinflammation to whole-eye visual performance. Measures optomotor-based visual acuity and contrast sensitivity as a non-invasive endpoint confirming whether a given neuroinflammatory mechanism produces functionally meaningful visual loss. Longitudinally repeatable without anaesthesia, enabling correlation of functional decline with inflammatory time course.
AcuiSee
Provides a cortically mediated, operant visual acuity endpoint for neuroinflammation and BRB breakdown studies in diabetic retinopathy. Assesses whether inflammatory retinal damage impairs learned visual discrimination.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Ge et al (2025) J Neuroinflammation.
    cGAMP-mediated STING pathway activation promotes iBRB breakdown in a DR model, with OptoDrum confirming that this vascular disruption produces a quantifiable visual acuity deficit.
  • Holden et al (2024) J Neurochem.
    In addition to its role as the longitudinal characterisation reference, the study documented neuroinflammation and neurovascular injury as histological correlates of the functional visual deficit, strengthening the case that OptoDrum-measured acuity loss reflects the neuroinflammatory retinal pathology of DR rather than a non-specific behavioural change.
  • Joussen et al. (2004) FASEB J.
    Retinal leucostasis and endothelial cell injury were established as the primary pathological events linking hyperglycaemia to vascular leakage and RGC death in DR, providing the mechanistic foundation for the neuroinflammatory pathway studies that now dominate the field. This study used rodent DR models with end-point histological endpoints. Striatech's OptoDrum delivers the functional behavioural complement to these structural measurements.
03
Can Visual Function Serve as a Non-Invasive Biomarker for Ischaemic CNS Injury and Stroke Severity?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Yes. Published studies using Striatech's OptoDrum in stroke and neurovascular injury models demonstrate that ischaemic CNS damage produces retinal visual function deficits that correlate with injury severity and that are detectable non-invasively without ophthalmological specialist equipment. For researchers studying stroke or systemic ischaemia whose primary subject is not vision, OptoDrum-measured visual acuity provides a rapid, quantitative, observer-independent functional biomarker that can be added to any behavioural battery without additional surgical procedures, anaesthesia, or increased animal numbers. When the research question specifically involves cortical visual recovery after stroke – including rehabilitation, cortical plasticity, or relearning of visual discriminations – AcuiSee is the appropriate complementary instrument, as it specifically requires cortical visual processing to generate a response.

The challenge

Stroke researchers face a persistent measurement problem: the most informative indicators of cortical injury severity and recovery – infarct volume, white matter tract integrity, cortical network reorganisation – require terminal histology or high-field MRI, both of which are resource-intensive and incompatible with repeated within-animal functional assessment. Standard behavioural tests for stroke in rodents – rotarod, cylinder test, adhesive removal, Morris water maze – assess primarily motor and sensorimotor function, which is confounded in stroke models by body weight loss, fatigue, and pain responses to the craniotomy. These tests are also insensitive to mild or moderate injury conditions where focal ischaemia affects cortical territories not directly controlling locomotion.

The visual pathway offers a complementary and orthogonal functional axis that is not confounded by motor deficit or locomotor capacity. In anterior circulation stroke models affecting the middle cerebral artery territory, the optic radiation, lateral geniculate nucleus, and primary visual cortex (V1) may all be involved, and the retinal vasculature is directly in the vascular territory affected by carotid and ophthalmic artery disease. Colon Ortiz et al. (2022, Cell Death Dis.) demonstrated that neurovascular injury following stroke produces measurable visual acuity deficits by OptoDrum, establishing the retinal OMR readout as a valid non-invasive biomarker of injury severity and treatment response in a vascular CNS injury paradigm. Yu et al. (2022, Biomaterials) extended this finding in a cell therapy study, showing that TNF-alpha- preconditioned neural stem cells improve both survival and visual function recovery after ischaemic injury .

An important distinction applies when the research question moves from detecting retinal injury to assessing cortical visual recovery after stroke. The OptoDrum measures the optomotor reflex, which is a subcortical reflex that does not require cortical visual processing. It is therefore well suited to detecting retinal and optic nerve pathway damage, but it is insensitive to selective cortical damage that leaves the retina and subcortical projection intact. If a stroke model specifically involves V1 or the optic radiation, and the research question concerns cortical visual representation, plasticity, or rehabilitation, AcuiSee is the appropriate instrument: its operant conditioning paradigm requires the animal to make a visually guided choice that depends on intact cortical visual processing. The two instruments together – OptoDrum for subcortical pathway integrity, AcuiSee for cortically mediated visual acuity – provide a complete functional profile of post-stroke visual recovery.

Also see: Trauma and Acute Injury and Neurovascular Injury

How Striatech products help

OptoDrum
Non-invasive, automated measurement of subcortical visual acuity and contrast sensitivity via the optomotor reflex. Detects visual function deficits arising from retinal and optic nerve neurovascular injury after stroke, providing a 4-minute, observer-independent functional biomarker of CNS ischaemic injury severity. Does not require ophthalmological expertise or surgical procedures.
AcuiSee
Measures visual acuity and contrast sensitivity via operant conditioning, a paradigm that requires cortical visual processing. Directly applicable when the stroke model involves V1 or the visual cortex, when post-stroke cortical visual recovery or rehabilitation is being studied, or when the research question requires distinguishing between subcortical and cortical visual deficits. The operant forced-choice approach maps more directly onto clinical visual acuity assessment, providing stronger face validity for translational stroke research targeting cortical visual function.
Non-aversive Animal Platform
Enables reliable OptoDrum testing in post-stroke animals that may be debilitated, pain-sensitised, or handling-averse following craniotomy or carotid surgery. The tunnel-lid design allows voluntary entry from the home cage, preventing stress-induced suppression of the optomotor response in neurologically compromised animals.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Colón Ortiz et al (2022) Cell. Death Dis.
    Journal Club →
    Neurovascular injury following experimental stroke produces quantifiable visual function deficits measurable by OptoDrum, establishing the OMR as a non-invasive biomarker of ischaemic CNS injury severity.
  • Yu et al (2022) Biomaterials
    OptoDrum was used as the primary functional endpoint in a cell-based neuroprotection study following stroke and retinal I/R injury, showing that TNF-alpha- preconditioned neural stem cells produce a measurable improvement in visual function recovery. The study demonstrates that OptoDrum is sensitive to treatment-mediated functional gains in an ischaemic CNS model, reinforcing its utility as a stroke treatment-efficacy biomarker.
04
What Are the Visual Consequences of Ischaemia-Reperfusion Injury and Post-Ischaemic Demyelination?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Retinal ischaemia-reperfusion injury and post-ischaemic white matter demyelination both produce measurable visual function deficits detectable by OptoDrum. Xue et al (2023) demonstrated that alleviating early demyelination after vascular ischaemia preserves visual function, connecting a white matter repair mechanism to a behaviourally measurable visual outcome. Yu et al (2022) showed that cell-based neuroprotection in a combined stroke and I/R model similarly improves optomotor-measured visual recovery. Together these studies establish that the dual ischaemic injury mechanisms – acute neuronal death from I/R and secondary white matter demyelination from ischaemic tissue injury – are both amenable to functional monitoring and intervention assessment using the OptoDrum.

The challenge

Vascular ischaemia injures the CNS through two temporally overlapping but mechanistically distinct processes. The first is acute neuronal and RGC death in the ischaemic core and penumbra, driven by excitotoxic glutamate release, oxidative burst, and mitochondrial failure within minutes to hours of the ischaemic event. The second is secondary white matter demyelination occurring in the hours to days following reperfusion: re-oxygenation generates reactive oxygen species that damage oligodendrocytes and myelin sheaths, producing the white matter lesions that contribute substantially to ischaemic stroke disability in humans. In the visual pathway, this secondary demyelination affects the optic nerve and optic radiation, producing a functionally distinct deficit from the acute RGC loss caused by retinal I/R.

Distinguishing these two components and evaluating interventions targeting each of them requires a functional endpoint that can track both acute deficit and subsequent recovery across the full ischaemic injury-and-repair time course. The OptoDrum's non-invasive, repeatable design is ideally suited to this requirement: it can be applied immediately after the ischaemic insult to document the acute visual deficit, then repeatedly over subsequent days and weeks to track both spontaneous and treatment-induced recovery trajectories. Xue et al (2023) exploited this capability, using OptoDrum to show that an intervention alleviating early optic nerve demyelination after ischaemia produces significantly better functional visual recovery compared with controls (Xue et al, 2023, Brain Pathol).

Also see: Neuroinflammation and Autoimmune CNS Disease, Retinal Ischaemia-Reperfusion Injury and Blindness

How Striatech products help

OptoDrum
Tracks the acute visual acuity deficit and subsequent recovery trajectory in the same animals following retinal I/R or ischaemic demyelination injury. Non-invasive and repeatable; enables day-by-day functional monitoring across the full injury-and-repair time course without anaesthesia or additional surgical procedures.
ScotopicKit
When ischaemia extends to the outer retina or when rod photoreceptors are differentially vulnerable to the ischaemic insult (as in prolonged IOP elevation protocols), scotopic OMR testing detects rod-specific functional deficits that photopic testing alone would miss, providing a more complete profile of ischaemic retinal injury.
DarkAdapt
Ensures consistent and complete dark-adaptation prior to scotopic OMR testing at each time point in the longitudinal I/R study, a prerequisite for reproducible scotopic acuity measurements.
AcuiSee
Provides a cortically mediated, operant visual acuity endpoint for ischaemia-reperfusion and post-ischaemic demyelination studies. Assesses whether ischaemic damage to retinal ganglion cells and optic nerve impairs learned visual discrimination, complementing the subcortical reflex readout from OptoDrum.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Xue et al (2023) Brain Pathol.
    An intervention targeting early post-ischaemic demyelination preserves visual function in a vascular injury model. OptoDrum was providing the functional endpoint confirming that white matter protection translates to improved optomotor performance.
  • Yu et al (2022) Biomaterials
    Cell-based neuroprotection improves visual function recovery after combined stroke and retinal I/R injury, with OptoDrum providing the primary functional endpoint. The study demonstrates that the same ischaemic mechanism that drives cerebral injury also produces a quantifiable retinal visual deficit and recovery trajectory, reinforcing the value of OptoDrum as a shared functional readout across stroke and I/R paradigms.
  • Zhao et al (2025) Invest Ophthalmol Vis Sci.
    Although this study applies primarily on the glaucoma and neuroinflammation application, it directly characterises complement-driven visual dysfunction in a retinal I/R model using OptoDrum, providing mechanistic context for the inflammatory amplification that follows retinal ischaemia-reperfusion.
05
Does Immunomodulatory or Neuroprotective Treatment Preserve Visual Function in Vascular and Inflammatory Retinopathy?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Yes – and OptoDrum provides the functional endpoint that confirms whether a given intervention translates structural retinal protection into a behaviourally meaningful visual benefit. Kinuthia et al (2025) demonstrated that immunomodulatory treatment in an inflammatory retinopathy model preserves optomotor-measured visual function, establishing that immune-targeting strategies can produce functional visual gains that are detectable non-invasively in rodents. For studies where the research question additionally concerns whether neuroprotection extends to cortical visual processing, AcuiSee is available as a complementary operant-based endpoint.

The challenge

A recurring translational gap in retinal neuroprotection research is the disconnect between histological rescue and functional preservation: neuroprotective agents frequently improve RGC counts, reduce microglial activation scores, and lower tight junction protein loss in histological and biochemical analyses, but whether these cellular benefits translate to improved visual performance in the same animal is often not tested. This disconnect matters for the clinical interpretation of preclinical data – patients and clinicians care about visual acuity outcomes, not RGC counts per se – and it matters for regulatory risk: a drug that rescues cells without restoring function has uncertain clinical value.

The OptoDrum fills this translational gap by providing a direct functional validation of structural neuroprotection. Kinuthia et al. (2025, JCI Insight) demonstrated this dual approach explicitly: alongside structural and immunohistochemical endpoints for retinal inflammation, OptoDrum confirmed that immunomodulatory treatment preserved visual acuity in the inflammatory retinopathy model . This combination – structural endpoints to establish mechanism, functional endpoint to establish clinical relevance – represents the current standard for preclinical retinal neuroprotection studies and is achievable using OptoDrum without any additional animal cohorts or terminal procedures.

Researchers working on immunomodulation in DR should also consider the intersection with the broader neuroinflammation field. The same microglial and complement pathways targeted in DR therapy are therapeutically implicated in EAE, optic neuritis, and other autoimmune demyelinating diseases. Also see: Neuroinflammation and Autoimmune CNS Disease, Retinal Degeneration, Retinal Ganglion Cell Dysfunction and Maintaining and Restoring Vision

How Striatech products help

OptoDrum
Provides the functional validation endpoint for retinal neuroprotection studies: measures whether immunomodulatory or neuroprotective treatment results in retained visual acuity and contrast sensitivity compared with untreated controls. Longitudinally repeatable, non-invasive, fully automated; enables pre-treatment baselines, post-injury declines, and treatment-phase recovery all to be tracked in the same animals across a single study.
AcuiSee
In treatment studies where the neuroprotective intervention is hypothesised to preserve or restore not just retinal function but cortical visual processing (for example, in DR models with advanced inner retinal loss, or in studies of anti-inflammatory treatments targeting cortical visual pathway integrity) AcuiSee provides the cortically- mediated operant complement to OptoDrum. Because AcuiSee requires the animal to make a learned visual discrimination, it specifically tests whether the visual signal reaching the cortex is sufficient to support decision-making, a distinction that the subcortical OMR cannot make.
Non-aversive Animal Platform
In long-duration treatment studies spanning weeks to months, the non-aversive platform reduces cumulative handling stress and ensures that between-group functional differences reflect genuine treatment effects rather than differential stress responses, particularly in diabetic animals whose stress response and autonomic regulation may be altered by metabolic disease.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Kinuthia et al (2025) JCI Insight.
    Immunomodulatory treatment preserves optomotor-measured visual function in an inflammatory retinopathy model. OptoDrum was used as a functional neuroprotection endpoint in a vascular/inflammatory retinal disease paradigm. The study confirms that immune suppression in the retinal microenvironment translates to a functionally meaningful gain in visual performance.    
  • Kern et al. (2001) Diabetes.
    This foundational study established that pharmacological intervention in DR can reduce acellular capillaries and pericyte loss in a rodent model, demonstrating proof-of-concept for anti-inflammatory and anti-glycation strategies.
  • Barber et al. (1998) J Clin Invest.
    Retinal neurodegeneration, including RGC apoptosis, precedes and is mechanistically separable from microvascular DR pathology, establishing the neurodegeneration-first paradigm that underpins modern neuroprotective treatment strategies in DR. Visual acuity measurement provide the in vivo functional readout that validates structural neuroprotection.
Product Fit

Summary: Striatech Products supporting your research questions

Research Question OptoDrum ScotopicKit AcuiSee Photorefractor Keratometer DarkAdapt Non-aversive Platform
Longitudinal measurement in DR models Yes Yes Yes* Yes (with ScotopicKit) Yes
Neuroinflammation and BRB breakdown in DR Yes Yes
Stroke as a non-invasive CNS biomarker Yes Yes** Yes
Ischaemia-reperfusion injury and demyelination Yes Yes Yes Yes (with ScotopicKit)
Immunomodulation and neuroprotection in retinopathy Yes Yes* Yes
*AcuiSee for DR and retinopathy treatment studies: applicable when the research question specifically concerns whether neuroprotection extends to cortical visual processing, or when the study design requires distinguishing subcortical (OMR) from cortical (operant) visual deficits to characterise the extent of visual pathway involvement. Not required for studies focused exclusively on inner retinal or subcortical pathway monitoring, where OptoDrum alone is sufficient. **AcuiSee for stroke: most directly applicable when the stroke model involves the posterior visual cortex, visual radiation, or lateral geniculate nucleus, and the research question concerns cortical visual recovery, plasticity, or rehabilitation. When the primary interest is retinal and neurovascular injury severity as a CNS biomarker, OptoDrum is sufficient and AcuiSee is not required. Photorefractor and Keratometer are not listed as applicable to any of the sections above, as they measure refractive state and corneal curvature respectively. They would become applicable if a study specifically investigated how chronic hyperglycaemia or ischaemia affects the refractive properties of the lens or cornea.
Measurement Modalities

Measuring Functional Visual Outcomes in Vascular and Metabolic Disease: Diabetic Retinopathy and Stroke: How Do Available Methods Compare?

The table below provides an honest comparison of the Striatech functional assessment instruments alongside other modalities routinely used in preclinical diabetic retinopathy, stroke, and ischaemic CNS injury research. The goal is to identify where each method adds unique value and where the Striatech tools are genuinely complementary to, rather than simply competitive with, established alternatives.
Modality What It Measures Invasiveness Anaesthesia Longitudinal Repeatability Automation Training Required 3Rs Impact Key Limitation in DR / Stroke Studies
OptoDrum (OMR) Photopic visual acuity and contrast sensitivity; subcortical retina-to-brainstem pathway integrity Non-invasive No Daily if required; no upper limit Fully automated Minimal Within-animal longitudinal design replaces multiple terminal cohorts; reduces total animal numbers Subcortical OMR only; does not detect selective cortical visual processing deficits (see AcuiSee)
AcuiSee (operant) Visual acuity and contrast sensitivity via cortically mediated forced-choice discrimination Non-invasive No Yes, after training (10–14 days); session-based Moderate Moderate; training phase required Refinement through food reward rather than aversive stimuli; training phase adds procedural burden Training phase duration; not suitable for models with severe cognitive or motivational impairment
OptoDrum + ScotopicKit Scotopic (rod-mediated) visual acuity and contrast sensitivity Non-invasive No Daily if required; dark-adaptation protocol needed Fully automated Minimal; dark-adaptation protocol required As OptoDrum; extends to outer retinal compartment Dark adaptation adds ~30 min per session; rod deficit interpretation requires comparison with photopic baseline
Flash ERG Photoreceptor (a-wave) and inner retinal (b-wave) electrical responses; outer and inner retinal function Minimally invasive (corneal electrode) Yes (typically) Limited by anaesthesia burden; typically weekly or biweekly Moderate Moderate to high; electrophysiology expertise required Provides outer retinal readout not captured by OMR; anaesthesia adds welfare burden Anaesthesia confounds in metabolic and diabetic models; not suitable for daily monitoring
Pattern ERG (PERG) RGC-specific electrical response; inner retinal function Minimally invasive Yes (typically) Limited by anaesthesia; typically weekly or less Low to moderate High; specialised expertise required Provides RGC-specific inner retinal readout complementary to OMR Anaesthesia burden; signal amplitude varies with electrode placement and fixation
Fluorescein angiography (FA) Retinal vascular leakage and perfusion; BRB integrity; microaneurysm count Invasive (fluorescein injection; pupil dilation) Yes Limited; typically monthly or less Low (image interpretation) High; specialised imaging equipment and expertise required Gold-standard vascular endpoint for DR; directly captures BRB breakdown Terminal or near-terminal procedure limits longitudinal frequency; does not confirm functional consequence of leakage
OCT (optical coherence tomography) Retinal layer thickness; RNFL and RGCL structural integrity; structural degeneration Non-invasive (mydriasis typically required) Yes (typically, for immobilisation) Weekly to monthly feasible Semi-automated (segmentation algorithms) Moderate; imaging and image analysis expertise required Structural endpoint; complements OMR functional data Structural readout only; does not confirm functional consequence of layer thinning
Histological endpoints (RBPMS RGC counts, acellular capillary counts, BRB permeability) RGC survival, pericyte loss, BRB integrity, microglial density Terminal Yes (terminal) None (terminal) Semi-automated (counting algorithms) Moderate; immunohistochemistry expertise required High 3Rs burden; separate cohorts needed at each time point Cannot confirm functional consequence; requires terminal procedure
Clinical and neurological scoring (body weight, blood glucose, motor deficit scoring) Gross metabolic and neurological status Non-invasive to minimally invasive No Yes Low (observer-dependent) Low to moderate Low animal burden; standard disease monitoring Not specific to visual pathway; cannot substitute for functional visual assessment
In most vascular and metabolic disease studies, the optimal experimental design couples OptoDrum (and AcuiSee where cortical visual function is a specific research question) with at least one vascular structural endpoint (FA or OCT) and at least one histological endpoint at the study termination time point. The Striatech instruments' primary contribution is the non-invasive, longitudinally repeatable functional layer that bridges between structural assessment time points, provides within-animal statistical power, and reduces the number of separate terminal cohorts required to characterise the full disease time course. For further information on Striatech instrument capabilities and product specifications, see the product pages at stria.tech.
Supported by Striatech Products

Publications on Vascular and Metabolic Disease: Diabetic Retinopathy and Stroke

Great Research, Interactive

Journal Clubs related to Vascular and Metabolic Disease: Diabetic Retinopathy and Stroke

Featured image for “Journal Club: RIP1 Inhibition Protects Retinal Ganglion Cells in Preclinical Glaucoma Models”
Q&A available
Watch now
Wednesday, 18 Jun 2025

Journal Club: RIP1 Inhibition Protects Retinal Ganglion Cells in Preclinical Glaucoma Models

Image
Bo Kyoung Kim, Ph.D. - Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
Image
This Journal Club features innovative research by Kim et al., who revealed that inhibiting RIP1 kinase protects retinal ganglion cells in preclinical glaucoma models. Their work demonstrates that targeting necroptosis and inflammation can prevent cell loss and functional decline, directly linking genetic risk to inflammatory degeneration and highlighting RIP1 as a promising therapeutic target for neuroprotection in glaucoma.
Featured image for “Journal Club: Aging and Injured Retinal Ganglion Cells Can Be Rejuvenated by Epigenetic Reprogramming”
Watch now
Thursday, 27 Feb 2025

Journal Club: Aging and Injured Retinal Ganglion Cells Can Be Rejuvenated by Epigenetic Reprogramming

Image
Bruce R. Ksander, Ph.D. - Schepens Eye Institute of Mass Eye & Ear, Harvard Medical School, Department of Ophthalmology
Image
This Journal Club highlights groundbreaking work by Harvard Medical School scientist Bruce R. Ksander and his team. They were able to reverse aging in retinal ganglion cells, improving visual function after injury or in disease.
Featured image for “Webinar: AcuiSee – Rodent Visual Acuity Using Behavioral Conditioning”
Watch now
Wednesday, 17 Nov 2021

Webinar: AcuiSee – Rodent Visual Acuity Using Behavioral Conditioning

Image
Dr. Jeffrey A Jamison - Experimentica Ltd.
Image
In this Webinar, Dr. Jeff Jamison will talk about “AcuiSee”, with which one can measure rodent vision based on an operant conditioning paradigm. Jeff is the developer of AcuiSee, and he now works as Director of In-Vivo Pharmacology at Experimentica.
Featured image for “Journal Club: The role of Nogo-A in visual deficits induced by retinal injury.”
Q&A available
Watch now
Thursday, 28 Jan 2021

Journal Club: The role of Nogo-A in visual deficits induced by retinal injury.

Image
Julius Baya Mdzomba, PhD - Université Laval
Image
Nogo-A is an inhibitor of neurite and axon growth that can limit CNS repair after injury. Neutralizing Nogo-A can aid recovery, including recovery of visual function after retinal injury. Baya Mdzomba and colleagues used OptoDrum to show improved optomotor visual function after Nogo-A neutralization in an NMDA-induced excitotoxic retinal-injury model.
Keep exploring

Related application areas, neighbouring research chapters, and the questions researchers ask most.

Research Chapter Vascular and Metabolic Disease: Diabetic Retinopathy and Stroke

Disruption of blood flow and glucose homeostasis driving retinal and CNS visual pathway injury. Diabetic retinopathy and ischemic stroke share neurovascular mechanisms and converge on quantitative visual endpoints.

7
Application Areas
5
FAQs answered
Part of CNS & Neurodegeneration
Main Application Areas
Diabetic Retinopathy
Neurovascular Injury
Retinal Ischemia-Reperfusion Injury
Stroke
Additional Topics
Blindness
Neuroinflammation
Retinal Degeneration

This page has been generated in part with support of AI. Before publication it has been reviewed by a Striatech editor.

Last updated: 15 July 2026